149 related articles for article (PubMed ID: 25943068)
1. Programmed cell death-1 inhibition in lymphoma.
Hawkes EA; Grigg A; Chong G
Lancet Oncol; 2015 May; 16(5):e234-45. PubMed ID: 25943068
[TBL] [Abstract][Full Text] [Related]
2. Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma.
Cheah CY; Fowler NH; Neelapu SS
Curr Opin Oncol; 2015 Sep; 27(5):384-91. PubMed ID: 26248256
[TBL] [Abstract][Full Text] [Related]
3. Where Do Programmed Death-1 Inhibitors Fit in the Management of Malignant Lymphoma?
Ansell SM
J Oncol Pract; 2016 Feb; 12(2):101-6. PubMed ID: 26869644
[TBL] [Abstract][Full Text] [Related]
4. PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas.
Wang Y; Wu L; Tian C; Zhang Y
Ann Hematol; 2018 Feb; 97(2):229-237. PubMed ID: 29128997
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune checkpoints in lymphoma.
Ansell SM
Curr Opin Hematol; 2015 Jul; 22(4):337-42. PubMed ID: 26049755
[TBL] [Abstract][Full Text] [Related]
6. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma.
Villasboas JC; Ansell S
Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012
[TBL] [Abstract][Full Text] [Related]
7. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
Tsirigotis P; Savani BN; Nagler A
Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
[TBL] [Abstract][Full Text] [Related]
8. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
9. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy.
Bryan LJ; Gordon LI
Blood Rev; 2015 Jan; 29(1):25-32. PubMed ID: 25260226
[TBL] [Abstract][Full Text] [Related]
10. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
11. Releasing the Brake on the Immune System: The PD-1 Strategy for Hematologic Malignancies.
Bryan LJ; Gordon LI
Oncology (Williston Park); 2015 Jun; 29(6):431-9. PubMed ID: 26091677
[TBL] [Abstract][Full Text] [Related]
12. Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Xia Y; Jeffrey Medeiros L; Young KH
Biochim Biophys Acta; 2016 Jan; 1865(1):58-71. PubMed ID: 26432723
[TBL] [Abstract][Full Text] [Related]
13. Novel immunologic approaches in lymphoma: unleashing the brakes on the immune system.
Nastoupil LJ; Neelapu SS
Curr Oncol Rep; 2015 Jul; 17(7):30. PubMed ID: 25986722
[TBL] [Abstract][Full Text] [Related]
14. [PD-1 blockade therapy in lymphoid malignancies].
Nishikori M; Takaori-Kondo A
Rinsho Ketsueki; 2017; 58(10):2043-2049. PubMed ID: 28978847
[TBL] [Abstract][Full Text] [Related]
15. PD-1-targeted immunotherapy: recent clinical findings.
Brahmer JR
Clin Adv Hematol Oncol; 2012 Oct; 10(10):674-5. PubMed ID: 23187774
[No Abstract] [Full Text] [Related]
16. Anti-PD-1 therapy in melanoma.
Homet Moreno B; Parisi G; Robert L; Ribas A
Semin Oncol; 2015 Jun; 42(3):466-73. PubMed ID: 25965365
[TBL] [Abstract][Full Text] [Related]
17. PD-1 blockade in Hodgkin's lymphoma: learning new tricks from an old teacher.
Allen PB; Gordon LI
Expert Rev Hematol; 2016 Oct; 9(10):939-49. PubMed ID: 27622603
[TBL] [Abstract][Full Text] [Related]
18. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer.
Henick BS; Herbst RS; Goldberg SB
Expert Opin Ther Targets; 2014 Dec; 18(12):1407-20. PubMed ID: 25331677
[TBL] [Abstract][Full Text] [Related]
19. [Anti-PD-1 antibody: basics and clinical application].
Tanaka Y; Okamura H
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1145-9. PubMed ID: 24047772
[TBL] [Abstract][Full Text] [Related]
20. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]